Cardiogenic Shock Outcomes Registry (COR-SHOCK): how patients fare over time

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

COR-SHOCK is a hybrid retrospective-prospective registry that collects real-world data on adults with cardiogenic shock to understand how therapies, monitoring, and patient factors relate to survival and prognosis. The study incorporates clinical, laboratory, imaging, and invasive hemodynamic data, including pulmonary artery catheterization, to capture the evolving complexity of cardiogenic shock. Data quality is maintained through semi-annual QA reviews and systematic data checks from electronic health records. There are no experimental interventions; participation involves standard care and observational data collection. The registry aims to identify trends in management and outcomes from 2017 onward to inform future practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

-Cardiogenic shock according to the following criteria:

Cardiac disorder resulting in hypotension, defined as at least one of the following:

* Systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or
* Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg

AND

Evidence of tissue hypoperfusion, defined by the presence of at least one of the following:

* Serum lactate \>2 mmol/L
* Acute kidney injury and/or oliguria
* Acute hepatic injury
* Cool or mottled extremities
* Altered mental status

AND

Clinical presentation judged to be primarily attributable to a cardiac etiology.

Exclusion Criteria:

* Age \< 18 years.
* Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).
* Refusal to participate in the study (applicable only to the prospective cohort).

Where it's running

• Unidade Local de Saúde de Lisboa Ocidental
  Carnaxide, Lisbon District, Portugal Recruiting

Study contacts

• Study coordinator: João Presume, MD
• Email: jppereira@ulslo.min-saude.pt
• Phone: +351 21 043 1000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimizing Impella 5.5 Outcomes With Advanced Data Science

  This study tests whether real-world data from Impella 5.5 patients with cardiogenic shock can help predict heart recovery and prevent complications, using advanced data science.

  Recruiting Medical University of Vienna · Vienna · NCT07619144

• Outcomes in patients with mixed cardiogenic and vasoplegic shock

  This registry will try to describe outcomes and risk factors in adults admitted with cardiogenic shock who also have inappropriate vasodilation (mixed cardiogenic‑vasoplegic shock).

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Somme · NCT07354568

• Factors Influencing Outcomes in ECMO and Impella Patients

  This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

  Recruiting Gottsegen National Cardiovascular Institute · Budapest · NCT07885618

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock

  This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07769528

• Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care

  In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07762560

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.